Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + Isoniazid
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
80
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
HIV Infection
Conditions
HIV Infection
Trial Timeline
Oct 1, 2011 โ Apr 1, 2016
NCT ID
NCT01380080About Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + Isoniazid
Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + Isoniazid is a approved stage product being developed by Allergy Therapeutics for HIV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01380080. Target conditions include HIV Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01380080 | Approved | Completed |
Competing Products
20 competing products in HIV Infection
Other Products from Allergy Therapeutics
Doravirine 100 Mg + Integrase strand transfer inhibitors + Tenofovir alafenamide/emtricitabine + tenofovir disproxil fumarate/emtricitabineApproved
80
Sofosbuvir/Velpatasvir (SOF/VEL)Approved
80
Transdermal estradiol gel + Micronized Progesterone + Placebo for estradiol gel + Placebo for micronized progesteroneApproved
80
Efavirenz + Emtricitabine/Tenofovir disoproxil fumarateApproved
80
Atazanavir + Didanosine (enteric-coated) + Efavirenz + Emtricitabine + Emtricitabine/Tenofovir disoproxil fumarate + Lamivudine/ZidovudineApproved
80